Global Epigenetics Drugs Market, By Type of Therapy (Histone Deacetylases (HDAC), DNA Methyltransferases (DNMT)), Applications (Oncology, Non-Oncology), Epigenetics Diagnostic Technologies (DNA Methylation and CHIP Technology), End-Users (Veterinary Hospitals, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Others), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) – Industry Trends and Forecast to 2030.
Epigenetics Drugs Market Analysis and Size
Epigenetics drugs are used as a precise inhibitors for each epigenetic condition, wherein identifying epigenetics drugs is important in drug discovery for epigenetic conditions. The market is still in its infancy; very few epigenetics drugs are recommended and approved for severe health conditions. The potential market valuation for epigenetics drugs is huge compared to other technologies in work.
Data Bridge Market Research analyses a growth rate in the epigenetics drugs market in the forecast period 2023-2030. The expected CAGR of epigenetics drugs market is tend to be around 19.3% in the mentioned forecast period. The market was valued at USD 9408.7 million in 2022, and it would grow upto USD 38,605.8 million by 2030. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Epigenetics Drugs Market Scope and Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2023 to 2030
|
|
Base Year
|
2022
|
|
Historic Years
|
2021 (Customizable to 2015 - 2020)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Type of Therapy (Histone Deacetylases (HDAC), DNA Methyltransferases (DNMT)), Applications (Oncology, Non-Oncology), Epigenetics Diagnostic Technologies (DNAMethylation and CHIP Technology), End-Users (Veterinary Hospitals, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
|
|
Market Players Covered
|
Eisai Inc. (U.S.), Novartis AG (Switzerland), Chroma Medicine (U.K.), Syndax (U.S.), ValiRx Plc (U.K.), Merck KGaA (Germany), Illumina, Inc. (U.S.), QIAGEN (Germany), Hoffmann-La Roche Ltd (Switzerland), Abcam plc (U.K.), Zymo Research Corporation. (U.S.), Cellcentric (Germany), Domainex (U.K.), Agilent Technologies, Inc. (U.S.), EpiGentek Group Inc. (U.S.), BioVision Inc. (U.S.), Bio-Techne. (U.S.), 4SC A.G. (Germany)
|
|
Market Opportunities
|
|
Market Definition
Epigenetics generally means the external modifications to DNA that turn genes into "on" or "off." These modifications usually do not lead to any change in the DNA sequence, though, they affect the reading of the cells genes. It emphasizes the study of cellular level and physiological characters inherited by daughter cells without causing any disruption in the DNA sequence. Therefore, epigenetics provides changes that present in gene expression, and these are considered as the important mechanisms of epigenetics. Therefore, epigenetics drugs are used to counter the dysregulation of epigenetic events that is caused by pathological conditions that can develop any further chronic diseases.
Epigenetics Drugs Market Dynamics
Drivers
- Increase in Cancer Cases
Cancer is spreading worldwide. As per the WHO, in 2020 there were over around 2.1 million new cancer cases globally. 70% of cancer deaths occur in low- and middle-income nations. Cancer kills 1 in 4 Americans. Uncontrolled DNA methylation can cause and advance cancer. Epigenetics has uncovered new cancer treatments. There are several cancer research studies using epigenetics that are well-funded. Epigenetics-based drugs are beneficial against a certain sort of cancer. Epigenetics targets only damaged and cancerous cells in the host.
- Growing Strategies for Drug Launches
Major market players operating in the market are focusing on growth strategies such as product approvals are anticipated to boost the market growth over the forecast period. For instance, in November 2021, Epizyme, Inc., a fully integrated, commercial-stage biopharmaceutical company developing and delivering novel epigenetic therapies, announced that the U.S. FDA had granted Fast Track designation to EZM0414. It is an investigational agent used to treat adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL).
Opportunities
- Higher Development of New Epigenetic Drug Candidates
Several companies operating in the market are widely engaged in developing new epigenetic drug candidates that are expected to create growth opportunities for the market during the forecast period. For instance, in April 2021, Celleron Therapeutics, a U.K.-based personalized medicines developing company, published the latest positive results of zabinostat. Furthermore, Zabinostat is an epigenetic immune regulator that activates genes involved in tumour antigen presentation and acts by stimulating cancer cells to present tumour antigens to T-lymphocytes, thus overcoming immune evasion. In addition to this, in CAROSELL Phase 2 clincal study, Celleron Therapeutics is investigating zabinostat and nivolumab combination treatment used for treating patients with microsatellite-stable colorectal cancer (MSS CRC). Likewise, in January 2021, Omega Therapeutics, Inc., which is a development-stage biotechnology company announced that it is advancing the development of OTX-2002, an Omega Epigenomic Controller development candidate to Investigational New Drug (IND)-enabling studies. It is a novel, engineered therapeutic solution particularly for controlling c-myc (MYC) oncogene expression.
Restraints/Challenges
- High Cost of Treatment
The vast expenditure related with the epigenetics drugs impede the market growth. The treatment becomes quite unaffordable in middle-income countries, thus, in a way limiting the market growth.
This epigenetics drugs market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the epigenetics drugs market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth
COVID-19 Impact on Global Epigenetics Drugs Market
COVID-19 left a major positive impact on epigenetics drugs market. There are several researchers that are performing to understand the epigenetics to prevent viral proliferation so that vaccines and therapeutics can be developed, particularly targeting the replicating mechanisms for COVID-19 virus. Thus, the increase in the researches associated with the epigenetics positively impacts the market.
Global Epigenetics Drugs Market Scope
The epigenetics drugs market is segmented on the basis of type of therapy, application, epigenetics diagnostic technologies, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Type of Therapy
- Histone Deacetylases (HDAC)
- DNA Methyltransferases (DNMT)
Applications
- Oncology
- Non-Oncology
Epigenetics Diagnostic Technologies
- DNAMethylation
- CHIP Technology
End User
- Hospitals
- Homecare
- Specialty Clinics
- Others
Distribution Channel
- Hospital Pharmacy
- Online Pharmacy
- Retail Pharmacy
Epigenetics Drugs Market Regional Analysis/Insights
The epigenetics drugs market is analyzed and market size insights and trends are provided by type of therapy, application, epigenetics diagnostic technologies, distribution channel and end-user as referenced above.
The major countries covered in the epigenetics drugs market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
Asia-Pacific has been witnessing a positive growth for epigenetics drugs market throughout the forecasted period due to increased new research and developments on epigenetics drugs market.
North America dominates the market due to the presence of key manufacturers of the product is high and, increasing research and development activities.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Global Epigenetics Drugs Market Share Analysis
The epigenetics drugs market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to epigenetics drugs market.
Key players operating in the epigenetics drugs market include:
- Eisai Inc. (U.S.)
- Novartis AG (Switzerland)
- Chroma Medicine (U.K.)
- Syndax (U.S.)
- ValiRx Plc (U.K.)
- Merck KGaA (Germany)
- Illumina, Inc. (U.S.)
- QIAGEN (Germany)
- Hoffmann-La Roche Ltd (Switzerland)
- Abcam plc (U.K.)
- Zymo Research Corporation. (U.S.)
- Cellcentric (Germany)
- Domainex (U.K.)
- Agilent Technologies, Inc. (U.S.)
- EpiGentek Group Inc. (U.S.)
- BioVision Inc. (U.S.)
- Bio-Techne. (U.S.)
- 4SC AG (Germany)
SKU-